BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/7/2020 1:54:39 AM | Browse: 658 | Download: 832
 |
Received |
|
2019-09-11 03:41 |
|
Peer-Review Started |
|
2019-09-11 03:41 |
|
To Make the First Decision |
|
2019-10-24 08:50 |
|
Return for Revision |
|
2019-10-25 09:18 |
|
Revised |
|
2019-11-05 19:24 |
|
Second Decision |
|
2019-11-13 11:52 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2019-11-13 23:38 |
|
Articles in Press |
|
2019-11-13 23:38 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-11-20 08:02 |
|
Publish the Manuscript Online |
|
2020-01-07 01:54 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Pembrolizumab - emerging treatment of pulmonary sarcomatoid carcinoma: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Emanuela Cimpeanu, Jibran Ahmed, Wahib Zafar, Adreana DeMarinis, Svetoslav S Bardarov, Shamim Salman and Dennis Bloomfield |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Emanuela Cimpeanu, MD, Doctor, Department of Internal Medicine, Richmond University Medical Center, 355 Bard Ave, Staten Island, NY 10310, United States. emma_ver@yahoo.com |
| Key Words |
Pembrolizumab; Pulmonary sarcomatoid carcinoma; Programmed death-ligand 1; Platinum-based chemotherapy; Non-small-cell lung cancer; Overall survival |
| Core Tip |
Pulmonary sarcomatoid carcinoma is classified as a rare and particularly aggressive subtype of non-small-cell lung cancer. In recent years, pembrolizumab, a humanized monoclonal IgG4-kappa isotype antibody against the programmed death 1 (PD-1) receptor, has become the first-line treatment for other subtypes of non-small-cell lung cancer, if programmed death-ligand 1 (PD-L1) expression is present on at least 50% of tumor cells. We report the case of an elderly man who came in with respiratory distress due to a large pulmonary mass, which was diagnosed as locally invasive pulmonary sarcomatoid carcinoma with PD-L1 greater than 50%. The patient was started on 200 mg of pembrolizumab every 3 weeks. After 5 cycles of pembrolizumab tumor burden had decreased by more than 80%. Further decrease was seen after the completion of 10 cycles and the patient’s functional status returned to baseline. The recommendation to treat pulmonary sarcomatoid carcinoma with pembrolizumab is supported by the small number of published papers available on this topic in the English literature. |
| Publish Date |
2020-01-07 01:54 |
| Citation |
Cimpeanu E, Ahmed J, Zafar W, DeMarinis A, Bardarov SS, Salman S, Bloomfield D. Pembrolizumab - emerging treatment of pulmonary sarcomatoid carcinoma: A case report. World J Clin Cases 2019; In press |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i1/97.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i1.97 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
